Uterine Cancer (Malignant Neoplasm) C&P Exam Prep

Hemoglobin (HGB) and Hematocrit (HCT)

What it measures: Blood counts to assess anemia related to cancer, cancer treatment, or abnormal uterine bleeding. The DBQ specifically captures HGB and HCT values.

What to expect: A blood draw or review of recent lab results. The examiner will document the most recent HGB and HCT values and the date of testing.

Pain considerations: Anemia-related fatigue can significantly worsen pelvic pain perception and overall functional capacity. Accurately describe how fatigue from anemia limits your daily activities.

Urinary Incontinence Severity Assessment

What it measures: Frequency and severity of urinary leakage, often a residual of pelvic radiation, radical hysterectomy, or fistula formation. Rated by how often absorbent material must be changed daily.

What to expect: The examiner will ask detailed questions about urinary leakage frequency, pad usage, and whether you use an appliance. They will assess whether you have urethrovaginal fistulas or other structural causes.

Pain considerations: Urinary urgency and leakage episodes can cause significant pain, embarrassment, and limit ability to work or participate in social activities. Describe the full functional impact, not just the physical symptom.

Pelvic Examination and Residual Assessment

What it measures: Physical assessment of surgical residuals, vaginal changes post-radiation, prolapse, fistulas, and any remaining gynecological structures.

What to expect: A pelvic examination to assess the vaginal vault, presence of vaginal stenosis or atrophy from radiation, cystocele, rectocele, prolapse, or fistulas. The examiner will note which organs have been surgically removed.

Pain considerations: Pelvic pain at rest and with activity, vaginal discomfort, and radiation proctitis all contribute to functional impairment. Describe your worst-day pain level and its specific triggers.

100%

Active malignancy (uterine cancer currently active and not in remission) OR while actively undergoing antineoplastic treatment (chemotherapy, radiation, immunotherapy, or hormonal therapy for cancer). A 100% rating is assigned from the date of diagnosis or onset of treatment and continues for 6 months following the date of the last treatment. After 6 months post-treatment, the rating is reduced based on residual disability.

From 38 CFR: Under 38 CFR 4.116, Note (a), a 100% rating shall be assigned from the date of diagnosis or commencement of antineoplastic therapy, whichever is earlier. Six months after the last treatment, the rating is reviewed and reduced based on residual disability under the appropriate diagnostic code.

100%

Post-treatment continued 100% rating: The 100% rating continues for 6 months following completion of the last antineoplastic treatment. During this period, the veteran continues at 100% regardless of response to treatment. After this period, rating is determined by residual disability.

From 38 CFR: Per 38 CFR 4.116 Note (a): a 100% rating shall be continued for 6 months following the cessation of any surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedures. Following this period, the rating is based on the severity of residuals.

30%

Post-treatment residual disability: After the 6-month period following last treatment, rating is based on residual conditions. A 30% rating typically applies to moderate residuals such as pelvic pain requiring continuous treatment, moderate urinary symptoms, moderate vaginal symptoms, or ongoing need for regular oncology follow-up without active disease. Specific residuals are rated under their applicable diagnostic codes (e.g., DC 7617 for removal of uterus; DC 7619 for removal of ovary).

From 38 CFR: After the mandatory 6-month 100% rating period following treatment completion, residuals of uterine cancer are rated under the most analogous gynecological diagnostic code. Pelvic pain, urinary symptoms, and surgical loss of organs are each rated separately and combined.

20%

Mild to moderate residual disability post-treatment: Mild pelvic pain, urinary symptoms not requiring frequent absorbent material changes, mild vaginal symptoms, or minimal treatment-related residuals. Applies when cancer is in confirmed remission and residuals are present but mild.

From 38 CFR: Residuals rated at mild-to-moderate level under applicable gynecological diagnostic codes following confirmed remission. Each residual condition must be individually evaluated and combined per 38 CFR 4.25.

0%

Complete remission with no significant residuals. Cancer is not active, all treatment is completed, and no residual symptoms or functional impairment attributable to the malignancy or its treatment are present. A 0% noncompensable rating may still establish service connection for future complications.

From 38 CFR: A 0% rating is assigned when the condition is in complete remission with no residual disability. However, maintaining service connection is important for future recurrence or late-onset residuals.

Active Cancer / Treatment Status

How to describe it: State clearly whether you are currently receiving treatment, when your last treatment was, and what type. Use precise dates. Distinguish between chemotherapy, radiation, surgery, immunotherapy, and hormonal therapy. State whether your oncologist has declared remission and on what date.

Example: My last chemotherapy infusion was on [date]. I am still experiencing severe nausea, fatigue so debilitating I cannot get out of bed for days after each cycle, hair loss, and mouth sores. On my worst days following treatment, I am completely bedridden and require assistance with basic self-care.

Examiner listens for: Clear timeline of diagnosis, treatment type, treatment dates, and current cancer status. The examiner needs to populate treatment completion dates and determine whether the 6-month 100% rating window applies.

Avoid: Do not say 'I'm doing okay' or 'the treatment is going well' without also describing the side effects and functional limitations. Do not omit treatments that have been completed - all treatment history affects the rating period.

Pelvic Pain and Pressure

How to describe it: Describe the location, quality (sharp, dull, cramping, burning), severity on a 0-10 scale, and frequency. Distinguish between constant and intermittent pain. Note what makes it worse (activity, intercourse, bowel movements, prolonged sitting or standing) and what provides relief.

Example: On my worst days, I have a constant, severe pelvic pain rated 8-9 out of 10 that radiates to my lower back and inner thighs. I cannot sit for more than 15 minutes, cannot walk more than one block, and the pain wakes me from sleep multiple times per night. Even with prescription pain medication, the pain is not fully controlled.

Examiner listens for: Severity classification (mild, moderate, severe), frequency, impact on function, and whether pain requires continuous treatment. These directly map to the pain severity checkboxes on the DBQ and support specific rating levels.

Avoid: Do not minimize pain by saying 'I manage it' or 'it's not that bad.' Report your typical worst-day level, not only your best day. Do not omit pain that interrupts sleep, work, or daily activities.

Urinary Incontinence and Bladder Symptoms

How to describe it: Describe the type (stress, urge, overflow, or continuous), frequency of leakage episodes, and how many pads or absorbent materials you change per day. State the size of pads and whether they are completely soaked. Mention any use of catheters, condom catheters, or other devices.

Example: I experience urinary leakage every time I cough, sneeze, or stand up quickly, and I also have sudden urge incontinence that does not give me time to reach the bathroom. On an average day I change 4-5 fully saturated pads. On my worst days, I change 6 or more and have had accidents that soaked through my clothing in public, causing me to limit leaving my home.

Examiner listens for: Specific number of absorbent material changes per day, whether an appliance is required, presence of fistulas, and impact on daily life. These directly determine which incontinence rating tier is checked on the DBQ.

Avoid: Do not underreport pad changes. Many veterans say 'I use pads' without specifying frequency. Do not omit embarrassment, social isolation, or work limitations caused by incontinence.

Treatment Residuals (Radiation, Chemotherapy, Surgery)

How to describe it: For radiation: describe vaginal stenosis, dryness, pain with intercourse, bowel changes (diarrhea, urgency, rectal bleeding), bladder urgency, and lymphedema. For chemotherapy: describe neuropathy (numbness, tingling in hands/feet), persistent fatigue, cognitive effects ('chemo brain'), nausea, and immune suppression. For surgery: describe what was removed, when, and the resulting hormonal and functional changes.

Example: Since completing radiation, I have severe vaginal stenosis that makes gynecologic exams extremely painful and has eliminated any ability to have sexual intercourse. I experience daily rectal urgency and 3-4 episodes of loose stools. I have chronic lymphedema in both legs that causes swelling, pain, and difficulty walking more than half a block. My chemotherapy-related peripheral neuropathy causes burning pain and numbness in my feet that worsens at night and prevents me from sleeping.

Examiner listens for: Specific residuals that can be separately rated, their severity, and functional impact. The examiner must document all residuals to ensure each is captured on the DBQ and potentially rated under separate diagnostic codes.

Avoid: Do not assume treatment side effects are temporary or irrelevant. Residuals from radiation and chemotherapy can be permanent and are ratable. Do not fail to mention bowel or bladder changes even if you think they are 'normal' after cancer treatment.

Functional and Occupational Impact

How to describe it: Describe specifically how your condition limits work, household activities, caregiving, exercise, and social participation. Use concrete examples: how many hours you can work, what tasks you can no longer do, how often you miss work or appointments, and what accommodations you require.

Example: I have been unable to return to my previous job as a [occupation] because I cannot stand for more than 20 minutes, require frequent bathroom access, and experience unpredictable fatigue and pain flares that prevent reliable attendance. I have missed more than 30 days of work in the past year due to treatment, recovery, and ongoing symptoms. I require help with grocery shopping, housecleaning, and childcare on my worst days.

Examiner listens for: Concrete functional limitations that support occupational impairment and overall severity. This information populates the functional impact section of the DBQ and supports TDIU claims if applicable.

Avoid: Do not say 'I do what I can' without explaining what you cannot do. Do not omit job loss, reduced hours, or career changes caused by your condition. Underreporting occupational impact is one of the most common reasons veterans receive lower ratings than warranted.

Frequency of Medical Care and Ongoing Treatment

How to describe it: State how often you see your oncologist, gynecologist, or other specialists. Describe ongoing treatments (hormonal therapy, maintenance medications, physical therapy for lymphedema, pelvic floor therapy). Note whether you are seen at a VA clinic or private facility.

Example: I see my oncologist every 3 months for surveillance imaging and bloodwork. I take daily hormone therapy and weekly physical therapy for lymphedema. I also take daily medications for pain, bladder urgency, and neuropathy. These appointments and treatments consume 2-3 days per month and require someone to drive me.

Examiner listens for: Whether the veteran is regularly seen at clinic, the intensity of ongoing treatment, and whether symptoms require continuous treatment. This helps establish severity and populates key DBQ fields about treatment status.

Avoid: Do not omit any ongoing treatments, even if they seem routine. Hormone replacement therapy, surveillance imaging, and lymphedema management are all active treatments that support rating severity.